Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Psoriatic Arthritis Treatment Market Poised To Hit $20.62 Billion By 2030 With A 9.5% CAGR
The psoriatic arthritis treatment market size has seen significant expansion in recent years. It is anticipated to increase from $13.17 billion in 2025 to $14.36 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.0%. The expansion observed during the past period was largely due to factors including the restricted availability of cutting-edge therapies, continued dependence on traditional NSAIDs and DMARDs, the rising occurrence of psoriatic arthritis, enhanced patient understanding, and the development of hospital and retail pharmacy infrastructure.
The psoriatic arthritis treatment market is anticipated to experience substantial expansion in the coming years, with projections indicating a rise to $20.62 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.5%. This growth during the forecast period is fueled by the emergence of interleukin inhibitors and JAK inhibitors, the increasing acceptance of biologics, the evolution of personalized medicine approaches, the growing adoption of telemedicine for managing chronic conditions, and enhanced governmental and insurance support for psoriatic arthritis therapies. Key trends identified for this period include the rising utilization of biologics and targeted synthetic DMARDs, a heightened awareness regarding the early diagnosis and effective management of psoriatic arthritis, the development of individualized treatment strategies for both joint and skin manifestations, the broadening of hospital and specialty pharmacy distribution networks, and the integration of telemedicine with remote monitoring for patients with psoriatic arthritis.
Get A Free Sample Report With In-Depth Market Insights:
Psoriatic Arthritis Treatment Market Development Factors: What’s Supporting Demand?
Rising healthcare expenditure is projected to boost the expansion of the psoriatic arthritis treatment market in the future. Healthcare spending, interchangeably called healthcare expenditure, signifies the financial allocation dedicated to funding healthcare services, products, and programs within a particular nation, area, or healthcare framework. This funding aids the diagnostic process by covering costs for medical appointments, lab tests, and imaging. Individuals with PsA frequently undergo thorough assessments to confirm their condition, determine the degree of joint impact, and identify any related health issues. As an illustration, in December 2024, data from the Centers for Medicare & Medicaid Services, a US-based agency overseeing Medicare and Medicaid, revealed that U.S. health care expenditures in 2023 saw a 7.5% rise, reaching $4.9 trillion, which translates to approximately $14,570 per person. Consequently, the expansion of healthcare spending is propelling the development of the psoriatic arthritis treatment market.
Psoriatic Arthritis Treatment Market Segment Analysis: What Are The Core Market Categories?
The psoriatic arthritis treatment market covered in this report is segmented –
1) By Drug Class: Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biologics, Other Drug Classes
2) By Route Of Administration: Oral, Parenteral, Topical
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Traditional NSAIDs, COX-2 Inhibitors
2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs, Targeted Synthetic DMARDs
3) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors, Other Biologics
4) By Other Drug Classes: Corticosteroids, Topical Treatments, Janus Kinase (JAK) Inhibitors
Psoriatic Arthritis Treatment Market Transformation Trends: What Innovations Are Driving Change?
Leading companies engaged in the psoriatic arthritis treatment market are securing approvals for new medications such as Cosentyx to enhance their market profitability. Cosentyx is a pharmaceutical product utilized for treating autoimmune conditions, including non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and enthesitis-related arthritis. For instance, in October 2023, Novartis, a Switzerland-based pharmaceutical corporation, announced that its novel drug Cosentyx had received approval from the Food and Drug Administration. Cosentyx operates as a human interleukin-17A antagonist, working by impeding the activation of a protein called IL-17A, thereby reducing potential patient side effects like edema, discomfort, and skin rashes. Cosentyx has been proven beneficial in managing the symptoms of psoriatic arthritis and can begin to show effects in as little as three weeks. It alleviates several psoriatic arthritis symptoms, such as joint pain and tenderness, back discomfort, and skin problems.
Psoriatic Arthritis Treatment Market Top Companies Driving Competitive Growth
Major companies operating in the psoriatic arthritis treatment market are AbbVie Inc., Amgen Astellas BioPharma K.K., Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Celgene Corporation, Novartis International AG, Eli Lilly and Company, Pfizer Inc., Merck & Co. Inc., AstraZeneca plc, Sanofi SA, Otsuka Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Bayer AG, Eisai Inc., Janssen Pharmaceuticals Inc., Gilead Sciences Inc., GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd.
View The Full Psoriatic Arthritis Treatment Market Report:
Psoriatic Arthritis Treatment Market Global Footprint: Which Region Leads The Industry?
North America was the largest region in the psoriatic arthritis treatment market in 2025. The regions covered in the psoriatic arthritis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
